Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “FOG-001 will be administered subcutaneous at assigned doses in continuous cycles of 28 days”In the company’s words, NCT05919264 on ClinicalTrials.gov
- Tested for
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid and 7 more
- Main trialPhase 1/2
- “The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).”In the company’s words, NCT05919264 on ClinicalTrials.gov
Other drugs for Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- 1 Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 1 Apr 2027 | FOG-001 in Locally Advanced or Metastatic Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026